969 related articles for article (PubMed ID: 15786516)
1. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
2. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.
Lambert BL; Chang KY; Tafesse E; Carson W
J Clin Psychopharmacol; 2005 Feb; 25(1):12-8. PubMed ID: 15643095
[TBL] [Abstract][Full Text] [Related]
3. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
5. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
6. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
8. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
9. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
10. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
11. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
12. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of antipsychotics: another look at the risk of diabetes.
Moisan J; Turgeon M; Desjardins O; Grégoire JP
Can J Psychiatry; 2013 Apr; 58(4):218-24. PubMed ID: 23547645
[TBL] [Abstract][Full Text] [Related]
14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
15. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.
Ramaswamy K; Kozma CM; Nasrallah H
Drug Saf; 2007; 30(7):589-99. PubMed ID: 17604410
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
[TBL] [Abstract][Full Text] [Related]
17. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
18. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
[No Abstract] [Full Text] [Related]
19. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
Guo Z; L'italien GJ; Jing Y; Baker RA; Forbes RA; Hebden T; Kim E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1326-32. PubMed ID: 21515328
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Cohen D
Pharmacopsychiatry; 2004 Jan; 37(1):1-11. PubMed ID: 14750042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
